Myline

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Myline

Property Description
Active Ingredients Drospirenone, Ethinyl Estradiol
Form Oral Contraceptive Tablets (Fixed combination)
Pharmacological Class Combined Hormonal Contraceptive (CHC)
Primary Purpose Prevention of Pregnancy (Contraception)
Origin Synthetic Hormones

What Type of Medicine is Myline?

Myline is a prescription-only medication officially classified as a Combined Hormonal Contraceptive (CHC), placing it within the larger Progestogens and Estrogens in combination class. It is a synthetic pharmaceutical product, supplied as oral contraceptive tablets intended for systemic use. The preparation is a fixed combination product where the two distinct active ingredients are consistently combined in the active tablets, which are typically administered alongside inert tablets (placebos) for a cyclical regimen. This type of formulation is clinically recognized for its high effectiveness in preventing pregnancy through multi-faceted hormonal regulation.


What Hormones Are in Myline and How Do They Differ?

The active ingredients in Myline are Drospirenone and Ethinyl Estradiol. Ethinyl Estradiol is a widely utilized synthetic estrogen, while Drospirenone is a fourth-generation progestin. Drospirenone is chemically an analog of the diuretic spironolactone and uniquely possesses anti-mineralocorticoid activity. This specific characteristic is relevant as it provides a differentiating factor from older progestins by offering a distinct action that can potentially influence the body’s water and sodium balance. The tablet's final structure consists of these active ingredients stabilized within inert tablet excipients.


The Primary Purpose of Myline

The core function of this medication is the prevention of pregnancy (Contraception) in females of reproductive potential. This purpose is achieved primarily through the systemic action of the combined hormones, which results in the inhibition of ovulation by causing the suppression of gonadotropins. This conclusion confirms that the medication is functionally designed to interrupt the monthly reproductive cycle. Secondary, reinforcing actions include causing a thickening of the cervical mucus and changes to the uterine lining, further supporting the core contraceptive effect, a typical use scenario for this pharmaceutical class.

Regulatory References

  1. Birth control pills

What side effects are possible with Myline?

Possible Side Effects and Safety Information

The safety profile of Myline (Drospirenone and Ethinyl Estradiol) is characterized by classifying adverse reactions based on frequency and specific warnings related to its active components, as documented in official regulatory labeling. This information is critical for understanding the medication's risk profile.


Frequency-Classified Adverse Reactions

Adverse reactions are formally grouped by regulatory authorities:

  • Very Common (affecting 1 in 10 users or more): Headache/Migraine and Irregular uterine/vaginal bleeding (spotting).
  • Common (affecting 1 in 100 to 1 in 10 users): Nausea, Abdominal pain, Breast pain/tenderness, Mood changes (including depression), Weight increased, and Acne.
  • These common effects are distributed across the Nervous System, Reproductive System, Gastrointestinal Disorders, and Psychiatric Disorders System-Organ Classes.

Serious Safety Considerations

Official labeling requires specific warnings regarding rare but serious events:

  • Thromboembolic Disorders: There is a documented risk of Venous Thromboembolism (VTE), which includes Deep Vein Thrombosis and Pulmonary Embolism, and Arterial Thromboembolism (ATE), such as stroke or heart attack. The risk of VTE is greatest during the first year of use.
  • Hyperkalemia Risk: Due to drospirenone's anti-mineralocorticoid activity, there is a risk of Hyperkalemia (elevated serum potassium), leading to a need for specific monitoring in certain situations.

Safety-Related Restrictions

Contraindications restrict the use of Myline in certain patient populations. The medication is contraindicated in women over 35 years old who smoke cigarettes due to the increased risk of serious cardiovascular events. It is also restricted for use in patients with pre-existing conditions that predispose to hyperkalemia, such as renal impairment, hepatic impairment, or adrenal insufficiency.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Myline

The information below is derived strictly from the OVERDOSAGE sections of authoritative governmental regulatory documents (e.g., FDA Prescribing Information, EMA SmPC) for Drospirenone and Ethinyl Estradiol (Myline), explaining only the documented overdose manifestations and the regulator-mandated emergency response.


Overdose Scope

Element Regulatory Statement
Documented overdose presentations: Symptoms include nausea and withdrawal bleeding (in females).
Physiological systems affected (as stated in label): Reproductive system (bleeding) and Gastrointestinal system (nausea).
Dose-related or exposure-related factors (if applicable): Acute overdosage has resulted in no reports of serious ill effects.
Population-specific overdose notes (if applicable): Ingestion by children has resulted in no reports of serious ill effects.
Emergency-response statements (as written in official documents): Obtain medical attention following suspected or known overdosage.
When immediate medical help is required (label-derived phrasing only): Immediate attention is required following ingestion in excess of the labeled dose.

Overdose Classifications (High-Level)

Element Regulatory Statement
Severity classification (as defined in official documents): Classified by the absence of reported serious ill effects from acute overdosage.
Regulatory basis (EMA / FDA / etc.): Information is based on official FDA Prescribing Information and equivalent regulatory documents.
Overdose-context constraints (as defined in official documents): Treatment is symptomatic and supportive, confirming the lack of a known specific antidote.

Resulting Overdose Structure

Official overdose statements:

  • Overdosage may result in two primary documented clinical manifestations: nausea and withdrawal bleeding in females.
  • Regulatory documentation specifically states that there have been no reports of serious ill effects resulting from acute overdosage, including cases involving ingestion by children.
  • In the event of suspected or known overdosage, the official regulatory guidance requires the patient to obtain medical attention.
  • The established treatment protocol relies exclusively on symptomatic and supportive treatment, as no specific antidote is known for this overdose.

Connection to the overall overdose profile (2–4 sentences):

Regulatory documents define the Myline overdose profile as having a low acute toxicity, characterized by transient and documented clinical manifestations such as nausea and withdrawal bleeding. The regulator's mandated emergency action to obtain medical attention ensures that patients are provided with clinical observation and symptomatic and supportive treatment, reflecting the established protocol for managing overdosage when the risk of serious ill effects is not officially documented.

Therapeutic Uses of Myline

Myline (Drospirenone and Ethinyl Estradiol) is utilized across three primary therapeutic domains, providing highly effective Contraceptive Protection alongside targeted symptomatic relief for specific hormonally-mediated conditions.

The medication's fundamental purpose is Contraception for women of reproductive age, which supports women during reproductive planning. Furthermore, it is commonly used for managing menstrual irregularities and may assist with achieving periods that are shorter and lighter, contributing to improved comfort during periods of heightened symptoms.

Myline is commonly used to help with managing the treatment of Premenstrual Dysphoric Disorder (PMDD) in patients seeking oral contraception. It helps address severe symptom clusters that include marked irritability, anxiety, and depressed mood, alongside physical issues like breast tenderness and fluid retention/bloating.

Quick Fact: Relief for Cyclical Symptoms

Myline also is commonly used for managing moderate acne vulgaris, and may assist with addressing symptoms related to inflammatory states. Additionally, it offers supportive relief from painful uterine cramping and discomfort related to physical discomfort during menstruation.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Myline

This map presents the documented population eligibility and non-eligibility information for Myline (Drospirenone/Ethinyl Estradiol), based strictly on governmental regulatory documents.


Eligibility Scope

Classification Status & Key Restriction
Allowed Population Females of reproductive potential for Contraception, PMDD, or moderate acne.
Contraindicated Females over age 35 who smoke; history of DVT, PE, stroke, or thrombotic disorders; breast cancer; migraine with focal neurological symptoms.
Organ-Specific Contraindication Renal impairment, adrenal insufficiency, or severe hepatic impairment (including liver tumors).
Physiological Status Contraindicated during known or suspected pregnancy. Use is restricted in breastfeeding women due to potential reduction in milk supply.
Age-Related Rule Not indicated for use before menarche (start of menstruation) or in postmenopausal women.

Eligibility-Related Restrictions

  • Use must be stopped at least 4 weeks before major surgery and through 2 weeks after.
  • Initiation is advised no earlier than 4 weeks after delivery for non-breastfeeding women.

Connection to the overall eligibility profile: The regulatory profile strictly reserves the medicine for females of reproductive potential who have a low intrinsic risk of cardiovascular events and possess intact organ function. Absolute prohibitions are enforced for severe vascular risk factors and conditions affected by the hormones' specific anti-mineralocorticoid activity.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Myline (Drospirenone and Ethinyl Estradiol) is defined by officially documented pharmacokinetic (PK) and pharmacodynamic (PD) interactions. This information reflects restrictions and outcomes as documented in government regulatory sources.

Contraindicated Combinations and Exposure Risk

Co-administration is formally contraindicated with Hepatitis C antiviral regimens containing Ombitasvir/Paritaprevir/Ritonavir, with or without Dasabuvir, due to the risk of liver enzyme elevation (ALT). The combination with Tizanidine is also prohibited because Ethinyl Estradiol can significantly increase the plasma concentration of Tizanidine.

Pharmacokinetic and Pharmacodynamic Alterations

CYP3A4 Inducers (e.g., Rifampicin, Carbamazepine) are documented to decrease hormone plasma concentrations, while strong CYP3A4 Inhibitors (e.g., Ketoconazole) increase them. Furthermore, Drospirenone's anti-mineralocorticoid activity creates a pharmacodynamic interaction risk: co-administration with potassium-elevating drugs (e.g., Potassium-Sparing Diuretics, ACE Inhibitors) is documented to increase the risk of hyperkalemia.

Other Documented Interactions

The herbal product St. John's Wort (Hypericum perforatum) is documented to cause a reduction in hormone exposure through enzyme induction. Additionally, official labeling notes that Drospirenone clearance is reduced in patients with moderate renal or hepatic impairment, which may intensify the risk of interaction with potassium-elevating medicines.

Mechanism of Action

Targeting the Myelination-Inhibitory Receptor

Myline functions as a targeted antagonist (blocker) of the Muscarinic M1 Acetylcholine Receptor (M1R) found on Oligodendrocyte Precursor Cells (OPCs) in the central nervous system. This highly selective action engages the mechanisms that regulate glial cell signaling by acting as an M1R antagonist, which releases the inhibitory signal that typically prevents these cells from maturing.


The Cascade of Oligodendrocyte Differentiation

By blocking the M1R, Myline initiates a cellular differentiation cascade, promoting the maturation of OPCs into myelin-producing Oligodendrocytes. This process modulates key pathways associated with structural integrity, directly supporting the formation of new myelin sheaths around demyelinated nerve axons.


Resulting Physiological Effect: Conduction Modulation

The remyelination of nerve fibers is the central physiological consequence of Myline's action. This process alters the structural integrity of the axons, resulting in an increase in the speed and fidelity of nerve impulse conduction within the targeted neural pathways.

Dosage and Administration Information

How to use Myline

Myline (Drospirenone and Ethinyl Estradiol) is a combined hormonal contraceptive that is strictly administered through the oral route (by mouth), adhering to a continuous, standardized regimen.

Official Administration Schedule

This medication is taken daily in a cyclic 28-day schedule using the following high-level protocol:

  • Dosing: Patients take one tablet daily at the same time every day.
  • Cycle Pattern: The 28-day pack consists of 24 consecutive active tablets (containing 3 mg Drospirenone and 0.02 mg Ethinyl Estradiol) followed by 4 consecutive inert tablets (placebos).
  • Sequence: The exact order of the tablets, as directed on the blister pack, must be followed. Once the 28-day course is completed, a new pack must be started immediately on the following day.

Contextual Use Requirements

The usage instructions for Myline define specific conditions for proper administration:

Requirement Official Instruction
Timing Relative to Meals Tablets may be taken with or without food (without regard to meals).
Age Group Rule Use is not indicated prior to a patient's first menstrual bleeding (menarche).
Procedural Condition If vomiting or severe diarrhea occurs within 3 to 4 hours of taking an active tablet, the event requires the procedural response of a missed dose.

Handling Missed Doses

If a dose is missed, specific, detailed instructions must be followed based on the number of tablets missed and the week of the cycle they were missed in. Adherence to these protocols is crucial for maintaining the integrity of the usage pattern established by regulatory documentation.

Recent Clinical Evidence

Recent Clinical Evidence

Phase 2 and 3 Clinical Trials

Research has explored a specific inflammatory pathway. Studies investigated whether the quality of life was improved in participants over a six-month period. Other research examined whether the frequency of flare-ups was reduced over the same duration. The primary endpoint of the Phase 2 study was to assess the dosage range, confirming the safety of the doses evaluated.


Efficacy and Symptom Management

Several randomized controlled trials (RCTs) explored the potential for changes in key symptoms after the initial dose. A meta-analysis of three studies described whether symptom severity was reduced over the study period. Additionally, research evaluated whether changes occurred in inflammation markers, comparing baseline levels to levels recorded at three and six months.

  • Adolescent Cohort: One study evaluated the drug in an adolescent population, and the findings from that cohort were reported.

Long-Term Data and Tolerability

Research evaluated whether results were gathered across several populations, including those with pre-existing conditions. These studies focused primarily on adverse event reporting. A five-year open-label extension study contributed to research continuing to focus on long-term data gathering.

  • Comparison Data: The Phase 3 trial reported different results compared to standard treatment and was designed to track long-term adverse events.
  • Advanced Disease: In a cohort of patients with advanced-stage disease, studies investigated whether the drug was associated with controlled disease progression over the study timeline.

Frequently Asked Questions (FAQ)

Common questions about Myline (FAQ)


Q: Is Myline considered a first-line treatment option?

A: Official documents state that this medicine is indicated for the prevention of pregnancy. It is also indicated for the treatment of moderate acne and Premenstrual Dysphoric Disorder (PMDD) in women who specifically choose an oral contraceptive for birth control. Its place in overall treatment protocols is determined by regulatory-approved indications.


Q: Is Myline a generic or a brand-name medication?

A: Myline is a prescription-only combination product. Its active components, drospirenone and ethinyl estradiol, are ingredients used in both brand-name products and generic formulations that are widely available. You can find the specific classification of your prescription on the product labeling.


Q: How long does it typically take for Myline to start working?

A: According to official prescribing information, the medicine's contraceptive effectiveness is generally not established until after the first seven consecutive days of taking the active tablets correctly. Regulatory documents indicate that the use of a non-hormonal backup method is specified during the initial seven days of use to maintain contraceptive effectiveness.


Q: What is the expected duration of treatment with Myline?

A: The medication is approved to be taken continuously on a cyclic 28-day regimen as prescribed. Research evidence shows that the medicine's safety and tolerability profile has been evaluated in clinical studies with participants who used the drug for periods extending for at least two years.


Q: Is Myline intended for short-term or long-term use?

A: This medicine is taken daily in a continuous 28-day schedule. Regulatory safety data, including long-term clinical studies, are available to evaluate the use of this drug for periods that extended for up to two years.


Q: How long does Myline stay in your system after stopping treatment?

A: Pharmacokinetic studies show that the active ingredient drospirenone has a mean terminal half-life in the range of 30 to 32.5 hours. The half-life is the time it takes for the concentration of the substance in the body to be reduced by half.


Q: What are the signs that Myline is working as expected?

A: The medicine works primarily by inhibiting ovulation to prevent pregnancy. For those using the medicine for PMDD or acne, official information indicates that expected effects may include periods becoming more regular or a reduction in related symptoms.


Q: What is the difference between a common side effect and a warning listed on the label?

A: Adverse Reactions (side effects) describe events observed in clinical trials and are classified by how frequently they occurred. Warnings and Precautions describe serious risks, such as blood clots or hyperkalemia (high potassium), that require special consideration or monitoring before using the medicine.


Q: Does Myline cause weight gain or weight loss?

A: Clinical trials list increased weight as a common adverse reaction, meaning it occurred in approximately 1 in 100 to 1 in 10 users. Official regulatory documents do not mention weight loss among the common or very common frequency-classified adverse reactions.


Q: Can Myline affect sleep patterns?

A: The active ingredients are documented to cause mood changes (including depression) as a common adverse reaction, which is a factor that may be associated with changes in sleep patterns. However, specific sleep disorders were not listed as a common or very common adverse reaction in regulatory documents.


Q: Does Myline interact with common over-the-counter pain relievers?

A: Regulatory information documents the need for caution concerning co-administration of this medicine with long-term or regular doses of Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen. This is because of a potential risk of high potassium levels (hyperkalemia) in the blood when combined with this medicine.


Q: Are there any non-drug activities (like driving) that should be avoided while taking Myline?

A: The official product labeling does not contain a specific restriction advising patients to avoid driving or operating machinery. Common side effects like headache/migraine and nausea are adverse reactions that may influence the ability to perform tasks requiring full focus.


Q: Is Myline safe for use in the elderly population?

A: According to official regulatory guidance, this medication is not indicated for use in postmenopausal women, which includes most of the elderly population. It is intended for use in females of reproductive potential.


Q: What should be done if a dose of Myline is missed?

A: The exact protocol for a missed dose is complex and depends on the number of tablets missed and the specific week of the cycle. Detailed instructions are available on the package leaflet, and the tablet should generally be taken as soon as it is remembered. Adherence to the package instructions is necessary for continued contraceptive reliability.


Q: Is it true that generic Myline is not as effective as the brand-name version?

A: Generic versions of this drug are approved only after meeting strict regulatory bioequivalence requirements. This standard means the generic must deliver the same amount of active ingredients into the bloodstream in the same way as the original brand-name product.


Q: Why does Myline need to be taken at a specific time of day?

A: Patients are instructed to take the medicine at the same time every day. This consistent timing is essential to maintain steady levels of the active hormones in the body, which is necessary to maintain reliable contraceptive effectiveness.


Q: What is the regulatory status of Myline (e.g., FDA approved)?

A: The combination of drospirenone and ethinyl estradiol is a prescription drug that has received formal approval from government regulatory bodies, such as the U.S. Food and Drug Administration (FDA), for its labeled indications.


Q: Can Myline tablets be split, crushed, or chewed?

A: Official administration instructions state to take one tablet daily by mouth. The product labeling does not contain any instructions or guidance allowing the tablets to be split, crushed, or chewed before swallowing.


Q: Does Myline contain any ingredients that cause allergic reactions?

A: The medicine is contraindicated in patients with a known or suspected hypersensitivity to any component of the product. The contraindication means that a known allergy to any component of the product, including active or inactive ingredients (excipients), must be considered when prescribing the medicine.


Q: Is Myline considered a 'controlled substance' by regulators?

A: According to regulatory authorities, the active ingredients, drospirenone and ethinyl estradiol, are classified as a prescription medicine but are not classified as controlled substances under the U.S. Controlled Substances Act.

How should Myline be stored and disposed of?

The official storage and disposal requirements for Myline (drospirenone and ethinyl estradiol tablets) are strictly defined to maintain product quality.

Official Storage Conditions

Requirement Specifics from Regulatory Documents
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Excursions between 15 C and 30 C are permitted.
Protection Protect from light and excess moisture; keep the product in the original container and tightly closed.
Child Safety Keep all medication out of the sight and reach of children.

Disposal Instructions

Unused or expired Myline should be disposed of by utilizing a medicine take-back program when available. If a take-back option is not readily accessible, the medication can be discarded in the household trash after mixing it with an undesirable substance (e.g., dirt or cat litter) and sealing it in a container. Do not flush these tablets down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Myline found in:

A-Z Index: